"
Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival"
written by Regiane S. S. M. Alencar, Luciana Kikuchi, Cláudia M. Tani, Aline L. Chagas, Cinira C. Camargo, Túlio E. F. Pfiffer, Paulo M. G. Hoff, Flair J. Carrilho,
published by
Journal of Cancer Therapy,
Vol.7 No.4, 2016
has been cited by the following article(s):
|
[1]
|
Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib
Revista da Associação Médica Brasileira,
2020
DOI:10.1590/1806-9282.66.3.275
|
|
|
|